Real‐world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea
暂无分享，去创建一个
B. Bellosillo | Arturo Pereira | A. Angona | R. Ayala | J. Hernández-Boluda | G. Carreño-Tarragona | V. García-Gutiérrez | F. Ferrer-Marín | A. Álvarez-Larrán | B. Xicoy | M. Gomez-Casares | E. Arellano-Rodrigo | J. Raya | M. Pérez-Encinas | C. Martínez | Montse Gómez | M. Mata-Vázquez | E. Magro | Rafael Del Orbe-Barreto | B. Cuevas | M. Fox | M. Garrote | G. Caballero | C. García-Hernández | I. Murillo | Lucía Guerrero | R. García | M. Gasior | R. Pérez-López | M. Ramírez | V. García‐Gutiérrez | J. Hernández‐Boluda | Rafael del Orbe-Barreto | Ilda Murillo | M. Gómez-Casares | M. Mata‐Vázquez